These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34263635)

  • 21. Association between plasminogen activator inhibitor‑1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis : A meta-analysis.
    Bae SC; Lee YH
    Z Rheumatol; 2020 Apr; 79(3):312-318. PubMed ID: 31428858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized, controlled trials.
    Blavnsfeldt AG; de Thurah A; Thomsen MD; Tarp S; Langdahl B; Hauge EM
    Bone; 2018 Sep; 114():172-180. PubMed ID: 29913256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors.
    Gu C; Zhao R; Zhang X; Gu Z; Zhou W; Wang Y; Guo J; Bao Y; Sun C; Dong C; Gao J
    Arch Osteoporos; 2019 Dec; 15(1):1. PubMed ID: 31802295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PTPN22 polymorphisms, but not R620W, were associated with the genetic susceptibility of systemic lupus erythematosus and rheumatoid arthritis in a Chinese Han population.
    Tang L; Wang Y; Zheng S; Bao M; Zhang Q; Li J
    Hum Immunol; 2016 Aug; 77(8):692-698. PubMed ID: 27166176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of percutaneous coronary intervention in patients with rheumatoid arthritis and systemic lupus erythematosus: an 11-year nationwide cohort study.
    Lai CH; Lai WW; Chiou MJ; Lin WC; Yang YJ; Li CY; Tsai LM
    Ann Rheum Dis; 2016 Jul; 75(7):1350-6. PubMed ID: 26286017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk of lymphoma development in autoimmune diseases: a meta-analysis.
    Zintzaras E; Voulgarelis M; Moutsopoulos HM
    Arch Intern Med; 2005 Nov; 165(20):2337-44. PubMed ID: 16287762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA.
    Cho H; Kim YW; Suh CH; Jung JY; Um YJ; Jung JH; Kim HA
    Lupus; 2016 Oct; 25(12):1341-8. PubMed ID: 26985011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy.
    Rentero ML; Amigo E; Chozas N; Fernández Prada M; Silva-Fernández L; Abad Hernandez MA; Rodriguez Barrera JM; del Pino-Montes J;
    BMC Musculoskelet Disord; 2015 Oct; 16():300. PubMed ID: 26472426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of treatments on cell adhesion molecules in patients with systemic lupus erythematosus and rheumatoid arthritis: a review.
    da Rosa Franchi Santos LF; Costa NT; Maes M; Simão ANC; Dichi I
    Inflammopharmacology; 2020 Apr; 28(2):363-384. PubMed ID: 31820195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Systemic autoimmune diseases].
    Kawai S; Takagi K; Kusunoki Y; Nishio S; Matsumoto N
    Nihon Rinsho; 2008 Jan; 66(1):130-6. PubMed ID: 18193552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
    Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
    Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of ultrasonographic joint and tendon findings in hands between early, treatment-naïve patients with systemic lupus erythematosus and rheumatoid arthritis.
    Ogura T; Hirata A; Hayashi N; Takenaka S; Ito H; Mizushina K; Fujisawa Y; Imamura M; Yamashita N; Nakahashi S; Kujime R; Kameda H
    Lupus; 2017 Jun; 26(7):707-714. PubMed ID: 27837198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between tumor necrosis factor polymorphisms and rheumatoid arthritis as well as systemic lupus erythematosus: a meta-analysis.
    Chen L; Huang Z; Liao Y; Yang B; Zhang J
    Braz J Med Biol Res; 2019 Mar; 52(3):e7927. PubMed ID: 30916218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
    Mendoza-Pinto C; Rojas-Villarraga A; Molano-González N; García-Carrasco M; Munguía-Realpozo P; Etchegaray-Morales I; Morales-Sánchez H; Berra-Romani R; Cervera R
    Atherosclerosis; 2020 Mar; 297():55-63. PubMed ID: 32078830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) in Japan: Multi-center retrospective descriptive study.
    Tsuda S; Sameshima A; Sekine M; Kawaguchi H; Fujita D; Makino S; Morinobu A; Murakawa Y; Matsui K; Sugiyama T; Watanabe M; Suzuki Y; Nagahori M; Murashima A; Atsumi T; Oku K; Mitsuda N; Takei S; Miyamae T; Takahashi N; Nakajima K; Saito S;
    Mod Rheumatol; 2020 Sep; 30(5):852-861. PubMed ID: 31483178
    [No Abstract]   [Full Text] [Related]  

  • 38. A comparison of rheumatoid arthritis and systemic lupus erythematosus trial design: a commentary on ways to improve the number of positive trials in SLE.
    Miles A; Pope JE
    Clin Exp Rheumatol; 2015; 33(5):671-80. PubMed ID: 26315693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tripterygium Glycosides Combined with Leflunomide for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Yang YJ; Deng Y; Liao LL; Peng J; Peng QH; Qin YH
    Evid Based Complement Alternat Med; 2020; 2020():1230320. PubMed ID: 32454846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.
    Cole S; Walsh A; Yin X; Wechalekar MD; Smith MD; Proudman SM; Veale DJ; Fearon U; Pitzalis C; Humby F; Bombardieri M; Axel A; Adams H; Chiu C; Sharp M; Alvarez J; Anderson I; Madakamutil L; Nagpal S; Guo Y
    Arthritis Res Ther; 2018 May; 20(1):85. PubMed ID: 29720240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.